Ertugliflozin to Reduce Arrhythmic Burden in ICD/CRT patientS (ERASe-Trial) - a Phase III Study
Status:
Recruiting
Trial end date:
2024-01-06
Target enrollment:
Participant gender:
Summary
The recent study is planned to investigate the impact of Ertugliflozin on total burden of
ventricular arrhythmias. Further objectives will be number of therapeutic interventions of
implanted devices, atrial fibrillation, heart failure biomarker and changes in physical
function quality of life, stress and anxiety.
Phase:
Phase 3
Details
Lead Sponsor:
Medical University of Graz
Collaborators:
Elisabethinen Hospital General Hospital Linz Klinik Ottakring Klinikum Klagenfurt am Wörthersee Klinikum Wiener Neustadt Medical University Innsbruck Medical University of Vienna Wilhelminenspital Vienna